Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.10 by 280 percent. This is a 69.49 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $2.93 million which missed the analyst consensus estimate of $4.40 million by 33.41 percent.